USA flag logo/image

An Official Website of the United States Government

Imaging Modality to Identify Angiogenesis

Award Information

Department of Defense
Award ID:
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
Intelligent Optical Systems, Inc.
2520 W. 237th Street Torrance, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2001
Title: Imaging Modality to Identify Angiogenesis
Agency / Branch: DOD / ARMY
Contract: DAMD17-01-C-0020
Award Amount: $69,995.00


The goal of this project is to develop intelligent imaging software for the automated identification and analysis of angiogenesis. The project will demonstrate the feasibility of using this innovative technique for clinical angiography.The formation of newblood vessels (angiogenesis) is a critical component in a variety of physiological and pathological processes, such as in the healing of wounds, bone fractures, and ulcers and other angiogensis related diseases. There is, however, no software specificallydesigned for analyzing angiogenesis. Intelligent Optical Systems, Inc. (IOS) proposes to develop a user-friendly innovative method for the automatic, reliable, rapid, sensitive, and accurate identification and analysis of angiographies acquired fromMagnetic Resonance Imaging, computerized tomography, or Doppler ultrasound. This method will use neural network assisted imaging analysis software to identify and analyze the angiogenesis.This software will be useful in the diagnosis of angiogenesis inbone fractures, ulcers, cancer growth and metastasis, diabetes-induced retinal pathy, rheumatoid arthritis, and coronary disease. In addition, the timely analysis of angiogenesis may help soldiers avoid unnecessary surgical interventions and reduce injurymorbidity and mortality resulting from complications.Over 1000 research laboratories and 200 companies are engaged in angiogenesis research and development. These studies will potentially benefit over 65 million surgical patients, 10 million eye patients,7 million heart patients, and over 9 million cancer patients in the U.S. IOS will demonstrate the feasibility of this new technology by using innovative imaging analysis to meet the requirements for the specific, rapid, and accurate diognosis of clinicalangiography.

Principal Investigator:

Allan Wang
Research Scientist

Business Contact:

Robert Lieberman
Sr. Vice President & CTO
Small Business Information at Submission:

2520 W. 237th Street Torrance, CA 90505

EIN/Tax ID: 954680779
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No